Table 1.
Baseline characteristic among the 3 groups
| Variables° | OCR (64) | RTX (36) | CLA (20) | p* |
|---|---|---|---|---|
| Female n, (%) | 42, (65.6) | 26, (72.2) | 13, (65) | ns |
| Age at disease onset (± mean, S.D.) (year) | 24.4 ± 9.5 | 23.7 ± 9.9 | 26.5 ± 10.2 | ns |
| Number of DMTs before NTZ | 1.3 ± 1.1 | 1.7 ± 1.1 | 1.1 ± 0.8 | ns |
| Number of relapses 12 m before NTZ start | 1.6 ± 1.1 | 1.4 ± 1.2 | 1.6 ± 0.9 | ns |
| Number of T2-weighted brain lesions 12 m before NTZ start | 28.2 ± 16.1 | 23.8 ± 12.5 | 21.6 ± 13.1 | ns |
| Number of T1-Gd + brain lesions 12 m before NTZ start | 1.6 ± 2.2 | 1.5 ± 1.7 | 1.0 ± 1.2 | ns |
| EDSS at NTZ start, median (interquartile range) | 3.0 (2.0–4.5) | 2.5 (2.0–4.0) | 2.0 (1.0–3.0) | ns |
| Number of NTZ infusions | 35.1 ± 26.9 | 40.3 ± 24.9 | 26.7 ± 15.8 | ns |
| EID (n, %) | 25 (39.1) | 11 (30.6) | 6 (30) | ns |
| EID duration (weeks) | 16 ± 3.2 | 15 ± 4.7 | 14 ± 5.1 | ns |
| Washout period (weeks) | 8 ± 4.2 | 7 ± 3.9 | 6 ± 2.9 | ns |
Data are expressed as mean ± S.D. when otherwise specified
DMT disease modifying therapy; EDSS Expanded Disability Status Scale; EID extended interval dose; NTZ natalizumab
*via χ2, Fisher exact test or ANOVA according to the nature of variables